Biopharma jobs boom in Massachusetts, though challenges still exist

Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.

By Jacob Bell • Aug. 27, 2019

Oklahoma judge orders J&J pay $572M in landmark opioid case

At issue was J&J's marketing of opioids Duragesic and Nucynta, as well as its supplying of API to other manufacturers via subsidiaries Noramco and Tasmanian Alkaloids.

By Ned Pagliarulo • Aug. 26, 2019

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff